trial

Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder

NCTId NCT00316303
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 236 (actual)
Sponsored by Dartmouth-Hitchcock Medical Center
Primary completion 2009-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
236 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2006-02
Primary completion
2009-04
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Twinrix

Sponsors

Dartmouth-Hitchcock Medical CenterLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

2
Stanley D. Rosenberg, PhDPrincipal Investigator
Lisa B Dixon, MD, MPHPrincipal Investigator

Sites

1 total
Baltimore, United States

Linked catalysts

1
Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Inte — primary completion2009-04

Facts & assertions

4 sourced
Enrollment
236
Phase
PHASE2
Primary Completion Date
2009-04
Status
COMPLETED
relationships
The graph out of here
drug
Twinrix
drug
lead_sponsor
Dartmouth-Hitchcock Medical Center
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Bipolar Disorder
indication
Schizoaffective Disorder
indication
Depression
indication
investigator
Stanley D. Rosenberg, PhD
person
Lisa B Dixon, MD, MPH
person